Health News

Mayo Clinic researchers and their international colleagues have discovered genetic variants that lead to severe arthritis for a subset of women when taking aromatase inhibitors to treat their breast cancer. This serious side effect is so painful that many women halt their lifesaving medication. The findings appear today in the online issue of Journal of Clinical Oncology.

Read more

Filed under: Pharmacy News
Tags: Arthritis, Breast Cancer, cancer, Genetic, Oncology, Online, Pharmacy

Related posts

• Mayo Collaboration Finds Source Of Breast Drug Side Effect (0)
  Mayo Clinic researchers and their international colleagues have discovered genetic variants that lead to severe arthritis for a subset of women when taking aromatase inhibitors to treat their breast cancer. This serious side effect is so painful that many women halt their lifesaving medication. The findings appear in the online issue of Journal of Clinical [...]
  
  
• Radioactive tracing agent can identify tumor-draining sentinel nodes in breast cancer, melanoma patients (0)
  Researchers say a new kind of tracing agent is more accurate than current methods in helping identify tumor-draining sentinel lymph nodes in breast cancer and melanoma patients. That's the finding in a new study that appears in the online version of the Annals of Surgical Oncology. Read more [tags] Pharmacy News [/tags]
  
  
• Neoprobe’s Lymphoseek Phase 2 study data published in Annals of Surgical Oncology (0)
  Neoprobe Corporation (NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that results from a Phase II study of Lymphoseek® (Tilmanocept) have been published online in the Annals of Surgical Oncology and demonstrate the tracing agent's ability to identify tumor-draining lymph nodes in breast cancer and melanoma patients. Read more [tags] Pharmacy News [...]
  
  
• ZIOPHARM Oncology commences Phase I/II study of Zybulin for metastatic breast cancer (0)
  ZIOPHARM Oncology, Inc., announced today it has initiated a Phase I/II study at Memorial Sloan-Kettering Cancer Center for the novel, mathematically - determined administration of oral indibulin (Zybulin™ or ZIO-301) in the treatment of metastatic breast cancer. Read more [tags] Pharmacy News [/tags]
  
  
• ZEN bust-enhancing supplements may increase risk of breast cancer (0)
  Women who use bust-enhancing dietary supplements containing the mycoestrogen zearalenone (ZEN), a naturally occurring toxin that widely contaminates agricultural products, could be increasing their risk of breast cancer. That is the warning from breast health experts in a paper published online ahead of print publication in the January issue of IJCP, the International Journal of [...]